Leisure Acquisition Corp. (LACQ) to Combine with Ensysce Biosciences, Inc. in $207M Deal

Feb 1, 2021 INTEL by Matt Cianci

Leisure Acquisition Corp. (Nasdaq:LACQ) has entered into a definitive combination agreement with clinical stage biopharmaceutical company Ensysce Biosciences, Inc. at an enterprise value of $207 million. The company’s mission and current product pipeline are focused on solving prescription drug abuse – a national priority. The combined entity is expected to trade on the Nasdaq under
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Leisure Acquisition Corp. (LACQ) to Combine with Ensysce Biosciences, Inc. in $207M Deal

Leisure Acquisition Corp. (LACQ) to Combine with Ensysce Biosciences, Inc. in $207M Deal

ByMatt Cianci